Male hypogonadism (part 2)

Main Article Content

Ye.V. Luchytskyy
V.Yе. Luchytskyy
M.D. Tronko

Abstract

The second part of the review shows the current approaches to the methods of diagnosis and treatment of various forms of hypogonadism in men.

Article Details

How to Cite
Luchytskyy, Y., V. Luchytskyy, and M. Tronko. “Male Hypogonadism (part 2)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 5, Oct. 2017, pp. 386-93, doi:10.22141/2224-0721.13.5.2017.110030.
Section
Lecture

References

Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59. doi: 10.1210/jc.2009-2354.

Nieschlag E, Behre HM, Nieschlag S, editors. Andrology: male reproductive health and dysfunction. 3th ed. Berlin: Springer-Verlag Berlin Heidelberg; 2010. 629 p. doi: 10.1007/978-3-540-78355-8.

Dohle GR, Arver S, Bettocchi C, et al. EAU Guidelines on Male Hypogonadism. EAU 2016. 26 p. Available from: http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf

Brinkman AO. Molecular mechanisms of androgen action – a historical perspective. Methods Mol Biol. 2011;776:3-24. doi: 10.1007/978-1-61779-243-4_1.

de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93  doi: 10.1186/1477-7827-9-93.

Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male. 2011 Mar;14(1):10-5. doi: 10.3109/13685538.2010.511325.

Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870-7. doi: 10.1210/jc.2008-0021.

Sykiotis GP, Hoang X-H, Avbelj M. et al. Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metab. 2010;95(6):3019-27. doi: 10.1210/jc.2009-2582.

Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241-7. doi: 10.1210/jc.2007-1245.

Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):561-76. doi: 10.1016/j.beem.2006.09.003.

Zitzmann M, Faber S, Nieshlag E. Assotiation of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-43. doi: 10.1210/jc.2006-0401.

Dreval AV, Red’kin YuA. Age-related hypogonadism: basic principles of diagnostics and treatment. Med aspekty zdorovia muzhchiny. 2016;3:73-76. (in Russian)

Luchytskyy EV, Luchytskyy VE, Tronko MD. Male hypogonadism (part 1). Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(4):281-9. doi: 10.22141/2224-0721.13.4.2017.106658 (in Ukrainian).

Tüttelmann F, Gromoll J. Novel genetic aspects of Klinefelter’s syndrome. Mol Hum Reprod. 2010 Jun;16(6):386-95. doi: 10.1093/molehr/gaq019.

Pühse G, Secker A, Kemper S, Hertle L, Kliesch S.Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl. 2011 Oct;34(5 Pt 2):e351-7. doi: 10.1111/j.1365-2605.2010.01123.x.

Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocr Metab. 2010;95(10):4542-8. doi: 10.1210/jc.2010-1314. doi: 10.1210/jc.2010-1314.

Jääskeläinen J. Molecular biology of androgen insensitivity. Mol Cell Endocrinol. 2012 Apr 16;352(1-2):4-12. doi: 10.1016/j.mce.2011.08.006.

Tajar A, Huhtaniemi IT, O’Neill TW, et al. EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012 May;97(5):1508-16. doi: 10.1210/jc.2011-2513.

Lawrence KL, Stewart F, Larson BM. Approaches to male hypogonadism in primary care. The Nurse Pract. 2017;42(2):32-7. doi: 10.1097/01.NPR.0000511774.51873.da.

Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010 Jul 8;363(2):123-35. doi: 10.1056/NEJMoa0911101.

Morgentaler A, Zitzman M, Traish AM, et al. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016;91(7):881-96. doi: 10.1016/j.mayocp.2016.04.007.

Lunenfeld B, Arver S, Moncada I, Rees DA, Schulte HM. How to help the aging male? Current approaches to hypogonadism in primary care. The Aging Male. 2015;15(4):187-97. doi: 10.3109/13685538.2012.729110.

Tajar A, Mcbeth J, Lee DM, et al. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older european men. Pain. 2011;152(7):1495-501. doi: 10.1016/j.pain.2011.01.048.

Sykiotis GP, Hoang XN, Avbelj M, et al. Congenital idiopatic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes. J Clin Endocrinol Metabol. 2010;95(6):3019-27. doi: 10.1210/jc.2009-2582.

Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314-329. doi: 10.1111/ijcp.12319.

Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month randomized , double-blind , placebo-controlled study. J Sex Med. 2010 Oct;7(10):3495-503. doi: 10.1111/j.1743-6109.2010.01931.x.

Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19. doi: 10.1210/jc.2011-1137.

Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Rev. 2005;14(9):2257-60. doi: 10.1158/1055-9965.EPI-04-0715.

Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014 Oct;13(10):1327-51. doi: 10.1517/14740338.2014.950653.

Thirumalai A, Berkseth KE, Amory JH. Treatment of Hypogonadism: Current and Future Therapies. F1000Research. 2017;6:1-10 doi: 10.12688/f1000research.10102.1. eCollection 2017.

Most read articles by the same author(s)

1 2 > >>